Regeneus announced that its Phase I STEP knee osteoarthritis (OA) trial met its primary safety endpoint at 12 months and produced promising signs of efficacy, including clinically meaningful reductions in pain for the majority of patients and improvement in knee cartilage volume. Separately, it has also been granted a key patent that protects Progenza in Japan until 2032. The positive data and patent grant will be helpful as the company seeks to advance licensing discussions for Progenza for
31 May 2017
Positive STEP data and Japan patent grant
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Positive STEP data and Japan patent grant
Cambium Bio Ltd (CMB:ASX) | 0 0 -7.7% | Mkt Cap: 25.1m
- Published:
31 May 2017 -
Author:
Dr Dennis Hulme -
Pages:
8
Regeneus announced that its Phase I STEP knee osteoarthritis (OA) trial met its primary safety endpoint at 12 months and produced promising signs of efficacy, including clinically meaningful reductions in pain for the majority of patients and improvement in knee cartilage volume. Separately, it has also been granted a key patent that protects Progenza in Japan until 2032. The positive data and patent grant will be helpful as the company seeks to advance licensing discussions for Progenza for